PayRetailers Appoints Philippe Laranjeiro as Chief Commercial Officer – to Drive Ambitious Growth Strategy
31.1.2023 11:00:00 EET | Business Wire | Press release
PayRetailers, LATAM’s leading all-in-one payment technology provider, has announced the appointment of Philippe Laranjeiro as Chief Commercial Officer (CCO). He will report to CEO Juan Pablo Jutgla, overseeing the company's commercial operations, supporting rapid growth and increasing market share – while accelerating service optimization.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230126005021/en/
Philippe Laranjeiro, Chief Commercial Officer (Photo: PayRetailers)
Fintech growth leadership
Laranjeiro joins Spain-based PayRetailers with an impressive track record in the high-growth paytech sector, with more than 20 years of experience cultivating and scaling inclusive, equitable, high-performance teams. A fintech and payments veteran, he has previously worked in leadership roles for multiple Silicon Valley companies, including Atchik, Netsize, VISA, and Citcon.
His appointment supports PayRetailers’ ongoing growth strategy in a year that has seen the company expand its footprint from seven to 11 offices, more than double its headcount to over 200, and acquire Paygol in Chile and Pago Digital in Colombia.
PayRetailers Founder and CEO, Juan Pablo Jutgla, said, "We are thrilled to add someone of Philippe’s caliber to our leadership team. He is a deeply experienced and uniquely skilled fintech leader who possesses a clear client-first mentality. His experience and expertise in commercial leadership will be invaluable as we continue to focus on growth, profitability improvement, and business performance.”
Leading LATAM’s digital transformations
A specialist in aligning talent strategy to business growth, Laranjeiro will lead PayRetailers’ sales, partnerships, customer engagement and success strategy.
Philippe Laranjeiro said, "I am excited to join the team at PayRetailers as we deploy our innovative technologies to empower merchants’ digital transformations and optimize new revenue streams.”
For more information about PayRetailers, please visit the company's website at https://payretailers.com
About PayRetailers
Founded in 2017, PayRetailers is a leading global provider of online payment services with Latin DNA. Through one direct API, one technology platform and one contract, PayRetailers offers global merchants the integration of more than 250 payment methods without the need of a local entity. PayRetailers platform provides businesses the ability to manage their payment ecosystem, analyze data, and simplify their customer experience through fully integrated solutions. PayRetailers is headquartered in Spain with regional offices in Argentina, Brazil, Chile, Colombia, Mexico, Costa Rica, Paraguay, and Peru.
Website: https://www.payretailers.com
LinkedIn: https://www.linkedin.com/company/pay-retailers/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230126005021/en/
Contact information
Press Media Department
press@payretailers.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom